Skip to main content

FDA Approvals: New Colon-Cleansing Drug for Colonoscopy Preparation


CLINICAL CONTEXT

The US Food and Drug Administration (FDA) has approved a new colon-cleansing drug, a dual-acting stimulant and osmotic laxative, for colonoscopy preparation. A previously available, low-volume oral phospho-soda preparation was removed from the market for safety reasons.
The advantage of a small-volume solution for bowel preparation is greater patient compliance, as use of large-volume cleansing preparations may be a deterrent to some patients for having the procedure. Increased use of screening colonoscopy and cleaner bowel allowing high-quality colonoscopy may improve screening rates and cancer detection.

STUDY SYNOPSIS AND PERSPECTIVE

The FDA has approved Prepopik, a new bowel preparation for cleansing the colon before colonoscopy.
When it becomes available, the dual-acting stimulant and osmotic laxative will be notable for its low volume, representing "the lowest volume active ingredient colon preparation available — with 10 ounces of prep solution," according to a news release.
The preparation consists of 2 packets of sodium picosulfate, magnesium oxide, and citric acid. In a split-dose regimen, patients dissolve the first packet of powder into water and drink the orange-flavored solution the night before a scheduled colonoscopy, and then do the same for the second packet the morning of the procedure.
If that split-dose regimen cannot be performed, patients may also take the drug as a day-before regimen in the afternoon and evening before a colonoscopy.
Patients are also advised to drink additional fluids during and after use of the preparation to reduce the risk for fluid and electrolyte imbalance.
The FDA's approval was based on two phase 3 trials involving about 1200 adult patients who were scheduled for colonoscopies. The patients were randomly assigned to either the split-dose or day-before regimen or to a control preparation consisting of a polyethylene glycol plus electrolyte solution and two 5-mg bisacodyl tablets, administered entirely the day before the colonoscopy.
In both studies, the new preparation achieved the primary endpoint of successfully cleansing patients' colons based on the Aronchick Scale and demonstrated noninferiority to the control preparation.
The most common adverse effects related to the new preparation in study 1, involving a split-dose treatment group (n = 305) compared with the control group (n = 298), were nausea (2.6% vs 3.7%), headache (1.6% vs 1.7%), and vomiting (1.0% vs 3.4%).
In study 2, involving a day-before dose of the new preparation (n = 296) vs the comparator (n = 302), the adverse effects were similar, including nausea (3.0% vs 4.3%), headache (2.7% vs 1.7%), and vomiting (1.4% vs 2.0%).
"The choice of a bowel cleansing regimen for colonoscopy should be based on a patient's health and personal preferences," said Victoria Kusiak, MD, deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, in an FDA news release. "[The] approval provides a new treatment option for patients and doctors to consider."
According to Ronald P. Fogel, MD, a gastroenterologist from the Digestive Health Center of Michigan in Chesterfield, the idea of a small-volume solution is an important selling point for a bowel preparation.
"A major advantage of Prepopik is the smaller volume," he told Medscape Medical News. "Patients dread taking the large-volume cleansing preparations, and for some it is a deterrent for having the procedure."
The market is open for a product that helps alleviate the discomfort of a large-volume preparation, he added.
"The oral phospho-soda prep that was removed from the market for safety reasons was very popular with patients," Dr. Fogel said. "Prepopik has the potential to fill a niche in the cleansing procedure market because of the relatively small volume ingested.
"Any changes that increase the use of screening colonoscopy and allow for high-quality colonoscopy [are] a huge benefit to our patients."
Gastroenterologist Michael L. Weinstein, MD, underscored the importance of the bowel preparation in a successful colonoscopy.
"Less volume means the patient is more likely to be able to complete it," said Dr. Weinstein, from Capital Digestive Care in Bethesda, Maryland.
"I tell patients the most unpleasant part of a colonoscopy is the prep, but the most important part is the prep," he said.
"If the colon is not clean, it doesn't matter how good the colonoscopist is at making the procedure comfortable or easy; if we can't see, the procedure may be a failure, and that's a lot of effort to have to waste."
More information on the new colon-cleansing drug is available on the FDA Web site.
Dr. Fogel and Dr. Weinstein have disclosed no relevant financial relationships.

CLINICAL IMPLICATIONS

  • The FDA has approved a new bowel preparation drug, a low-volume, dual-acting stimulant and osmotic laxative, for colon cleansing before colonoscopy. This new preparation will be available as a split-dose regimen of 2 packets of powdered sodium picosulfate, magnesium oxide, and citric acid, to be mixed in water. Patients should be encouraged to drink additional fluids during and after use of the new preparation.
  • FDA approval was based on data from two randomized phase 3 trials enrolling approximately 1200 adults undergoing colonoscopy. Preparation in the control group consisted of a solution containing polyethylene glycol and electrolytes, and two 5-mg bisacodyl tablets, given on the day before the procedure. Both studies reached the primary endpoint for the new preparation and showed noninferiority to the control preparation for successful colon cleansing.
  • In these two randomized phase 3 trials, the most common adverse effects associated with the new bowel preparation, and also reported in the control group, were nausea, headache, and vomiting.

Comments

  1. Unknown18 April 2013 at 22:30

    This should be a good news for many because our present time has dictated us to take in a bunch of different foods without being conscious of our health. Having a the colon cleansed has a great impact in having a better health.

    ReplyDelete

Post a Comment

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

EHR Work Measures Proposed to Address Burnout

Electronic health record (EHR) vendors should imbed metrics into their systems to measure how EHRs affect clinicians' work, experts write in a commentary  published online  October 10 in the  Annals of Internal Medicine . Yumi T. DiAngi, MD, a fellow in clinical informatics at Stanford University School of Medicine in Palo Alto, California, and colleagues propose six areas metrics should cover and recommended the creation of a "national council of clinicians" to design measures and create guidelines to address privacy and other issues. "The EHR, which was intended to improve patient care, has had the ironic and unintended consequence of impairing practice efficiency, largely because of poor design, a focus on regulatory reporting, and the burden placed on clinicians by data entry," they write. EHRs have also led to high levels of burnout as physicians' satisfaction in their work has declined, they note. To gain insight into the stresses that have pro...
Post a Comment
Read more